Envestnet Asset Management Inc Lumos Pharma, Inc. Transaction History

Envestnet Asset Management Inc

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 08, 2024	BUY	$2.19 - $3.04 $7,358 - $10,214	3,360 Added 20.85%	19,475 $45,000
Q1 2024 May 13, 2024	BUY	$2.64 - $3.22 $11,016 - $13,437	4,173 Added 34.94%	16,115 $45,000
Q4 2023 Feb 13, 2024	BUY	$2.81 - $4.27 $1,396 - $2,122	497 Added 4.34%	11,942 $37,000
Q3 2023 Nov 13, 2023	SELL	$2.63 - $3.49 $520 - $691	-198 Reduced 1.7%	11,445 $37,000
Q2 2023 Aug 04, 2023	SELL	$3.01 - $4.38 $403 - $586	-134 Reduced 1.14%	11,643 $38,000
Q1 2023 May 11, 2023	BUY	$3.16 - $4.0 $4,006 - $5,072	1,268 Added 12.07%	11,777 $38,000
Q4 2022 Feb 07, 2023	BUY	$3.05 - $9.52 $32,052 - $100,045	10,509 New	10,509 $37,000
Q1 2022 May 04, 2022	SELL	$6.58 - $10.09 $68,221 - $104,613	-10,368 Closed	0 $0
Q4 2021 Feb 04, 2022	BUY	$6.84 - $10.04 $70,917 - $104,094	10,368 New	10,368 $72,000

2.2M

Ticker LUMO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 8,396,070
Market Cap $36.4M
Description
Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency and other rare en...

Get notified when there are updates to the investment portfolio of Envestnet Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Envestnet Asset Management Inc with notifications on news.